Between now and 2030, the biopharma sector is expected to be rocked by a number of high-profile patent cliffs that are likely to reshape the market in potentially unpredictable ways. A “patent cliff” refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch.
Although use of telehealth in clinical trials is not new, the modality was not popularized until social distancing efforts brought about by COVID-19 forced the issue. Companies interested in providing clinical trial services via telehealth have to deal with whether the carrying out the clinical aspects of a clinical trial is part of the practice of medicine.
The presence of private equity (PE) investment has exploded in recent years in all areas of the health care sector. PE in health care is a good thing when done right: It can pave the way for much needed innovation, efficiency, and nontraditional care delivery models. However, government regulators, media journalists, some health care practitioners, and private parties are watching PE investment with growing suspicion that profit-driven goals may conflict with the quality of care for patients.
Womble Bond Dickinson hosted a panel discussion on the current challenges involving data retention and e-discovery. In particular, the session looked at employee use of personal devices for business purposes, as well as a growing trend by digital messaging platforms to automatically delete messages shortly after they are delivered. This article is taken from that panel discussion.
The Personalized Medicine Coalition (PMC) recently released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022 (“Report”). As summarized in the Report, 2022 milestones include progress in diagnostics, therapeutics and new treatment modalities that are covered in this resource from Foley and Lardner LLP.
With the pandemic, there came a digital health explosion, with companies working swiftly to bring new technologies to light that would pave the way forward in telehealth and other critical areas. We saw an incredible interest in this space then, but what is the state of digital health now? This resource from Foley & Lardner LLP looks at data from public and private financing markets in the digital health space in 2022, and look forward to what to expect in 2023.
With the health care industry under pressure to improve patient outcomes while controlling costs, artificial intelligence (AI) and machine learning (ML) are quickly becoming indispensable tools. These technologies show promise in supporting decision-making, enhancing the delivery of care, and personalizing medicine. This resource from Foley & Lardner explores opportunities for health care organizations deploying AI-based solutions.
This resource provided by Foley & Lardner LLP covers the DOJ’s announcement on February 6th of their withdrawal of the 2011 Statement of Antitrust Enforcement Policy Regarding Accountable Care Organizations Participating in the Medicare Shared Savings Program (2011 ACO Statement) in addition to two other health care antitrust policy statements.
This resource from Seyfarth & Shaw LLP discusses the Securities and Exchange Commission's proposal for three new sets of rules (the “Proposed Rules”), as well as key considerations for the future based on this proposal.
It seems to us that although the dizzying number of technology solutions entering the market daily (not to mention the avalanche of new AI possibilities that accompany them) are intended to make everyone’s life simpler, it’s more challenging than ever to cut through the noise and figure out how or where to start your journey to simplifying contracting for you and your organization. Read more.